Shares of MannKind have seen some wild swings recently, and one institution-sized trader is making a big bet that the drug company will snap back up by 50 percent before mid-May. Read More
In less than two weeks, there've been four pretty significant events in biopharma. And, hopefully, after ADA things will begin to settle down a bit for the summer. Read More